- Home
- TLSA vs GNTA Comparison
TLSA vs GNTA Comparison
Compare TLSA & GNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TLSA | GNTA |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | United Kingdom | Italy |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 182.7M | 34.0M |
| IPO Year | 2000 | 2021 |
Fundamental Metrics
Financial Performance| Metric | TLSA | GNTA |
|---|---|---|
| Price | $1.49 | $1.44 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 414.9K | 92.8K |
| Earning Date | 01-01-0001 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.63 | $1.28 |
| 52 Week High | $2.60 | $10.00 |
Technical Indicators
Market Signals| Indicator | TLSA | GNTA |
|---|---|---|
| Relative Strength Index (RSI) | 39.51 | 36.07 |
| Support Level | $1.45 | $1.28 |
| Resistance Level | $1.62 | $1.68 |
| Average True Range (ATR) | 0.16 | 0.17 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 35.58 | 27.42 |
Price Performance
Historical ComparisonAbout TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.
About GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.